These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 16128684

  • 21. Clinical outcome of Crohn's disease treated with infliximab.
    Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tözün N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dökmeci A.
    Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957
    [Abstract] [Full Text] [Related]

  • 22. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G.
    Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
    [Abstract] [Full Text] [Related]

  • 23. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 24. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
    de Ridder L, Escher JC, Taminiau JA.
    Ned Tijdschr Geneeskd; 2002 Oct 05; 146(40):1879-83. PubMed ID: 12395595
    [Abstract] [Full Text] [Related]

  • 25. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS, Markowitz J, Wyllie R.
    J Pediatr; 2000 Aug 05; 137(2):192-6. PubMed ID: 10931411
    [Abstract] [Full Text] [Related]

  • 26. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep 05; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 27. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr 05; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 28. [Indications and results of infliximab in Crohn's disease].
    Karoui S, Boubaker J, Filali A.
    Tunis Med; 2004 Dec 05; 82(12):1057-63. PubMed ID: 15822505
    [Abstract] [Full Text] [Related]

  • 29. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 05; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 30. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
    Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
    Am J Gastroenterol; 2002 Jun 05; 97(6):1458-62. PubMed ID: 12094865
    [Abstract] [Full Text] [Related]

  • 31. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar 05; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 32. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ.
    N Engl J Med; 1999 May 06; 340(18):1398-405. PubMed ID: 10228190
    [Abstract] [Full Text] [Related]

  • 33. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec 06; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 34. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H.
    Br J Dermatol; 2007 Feb 06; 156(2):329-36. PubMed ID: 17223874
    [Abstract] [Full Text] [Related]

  • 35. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
    Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P.
    Gastroenterology; 2003 Jul 06; 125(1):32-9. PubMed ID: 12851868
    [Abstract] [Full Text] [Related]

  • 36. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 37. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
    Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ.
    Am J Gastroenterol; 2006 May 10; 101(5):1030-8. PubMed ID: 16606351
    [Abstract] [Full Text] [Related]

  • 38. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
    Persoons P, Vermeire S, Demyttenaere K, Fischler B, Vandenberghe J, Van Oudenhove L, Pierik M, Hlavaty T, Van Assche G, Noman M, Rutgeerts P.
    Aliment Pharmacol Ther; 2005 Jul 15; 22(2):101-10. PubMed ID: 16011668
    [Abstract] [Full Text] [Related]

  • 39. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
    Matsumoto T, Iida M, Motoya S, Haruma K, Suzuki Y, Kobayashi K, Ito H, Miyata M, Kusunoki M, Chiba T, Yamamoto S, Hibi T.
    Dis Colon Rectum; 2008 Jun 15; 51(6):916-23. PubMed ID: 18322754
    [Abstract] [Full Text] [Related]

  • 40. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM, Krauss N, Voll RE, Nägel A, Weidenhiller M, Konturek PC, Hahn EG, Raithel M.
    Digestion; 2008 Jun 15; 78(4):195-200. PubMed ID: 19122456
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.